<ul data-eligibleForWebStory="false"><li>Biocon Biologics has received marketing authorization from the European Commission for Vevzuo and Evfraxy biosimilars of Denosumab, used in treating various bone diseases.</li><li>Vevzuo is authorized for preventing bone complications in adults with advanced cancer involving bones, while Evfraxy is authorized for treating osteoporosis and bone loss in different conditions.</li><li>The approval of these biosimilars demonstrates Biocon's dedication to expanding patient access to essential medicines, particularly in the realm of bone health.</li><li>Biocon Biologics' CEO spoke about the company's successful regulatory approvals for biosimilars in the European region, highlighting the achievement with the Denosumab biosimilars.</li></ul>

Biocon Biologics Granted Marketing Authorisation By European Commission For Bone Disease Medicines

Discover more